WELL Health Completes Acquisition of MyHealth

Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan – En-Route to Commercialization of its Radiation Shielding Technology

"We are pleased by the ongoing validation of our radiation shielding technology's differentiation," said Mr. Jonathan Yifat, CEO of Radiaction Medical. "As we are nearing commercialization, these patents strengthen our strategic IP assets and further our mission to provide a safe environment for healthcare teams in the interventional suite," added Mr. Yifat.

The LimFlow System Found to be Cost-Effective, According to the Newest Study Published in the Journal of Critical Limb Ischemia

Percutaneous Deep Vein Arterialization (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation in a new study, published June 2021.

WELL Health Technologies Corp. (TSX: WELL) (“WELL” or the “Company“), a company focused on consolidating and modernizing clinical and digital assets within the healthcare sector, is pleased to announce it has completed the previously announced acquisition of all of the issued and outstanding shares of MyHealth (the “Transaction“) for a total  purchase price of C$206M plus a future conditional earn-out of up to $60M.

Founded in 2013, MyHealth has over 760 physicians and other healthcare professionals providing primary care, specialty care, telehealth services and accredited diagnostic health services from 48 locations across Ontario.

Hamed Shahbazi, Chairman and CEO of WELL commented, “We extend a warm welcome from the WELL family to the talented MyHealth team.  The closing of this acquisition offers not only financial value for our shareholders, but also supports our value system at WELL as MyHealth has been built upon important pillars that we hold in high regard including: a progressive and award winning workplace culture; a forward-thinking network of health practitioners who embrace technology; and the vision of empowering patients through the provision of digital tools and technologies.  We are very excited for the extended reach and depth that MyHealth offers WELL.”

MyHealth offers primary care consultations both in-person and through telehealth, as well as diagnostic services related to cardiology, women’s health, bone/muscle health and cancer diagnostics.  For the twelve months ended March 31, 2021, MyHealth recorded over 500,000 patient visits including primary, specialty, telehealth, and diagnostic visits.  MyHealth has been growing rapidly over the past five years, with a 40% CAGR3 in both revenue and EBITDA1.  This growth includes 15% organic growth rate over that period plus a disciplined and successful acquisition program with 25 completed deals over the past eight years.  MyHealth will continue to pursue its accretive M&A program and has an active pipeline including over 125 potential targets.

With the acquisition of MyHealth, WELL becomes the largest owner-operator of outpatient medical clinics in Canada providing primary, allied, specialized and diagnostic healthcare services.  Furthermore, approximately 75% of MyHealth’s medical consultations are conducted via telehealth, which when combined with WELL’s multiple telehealth businesses, make WELL the leading multi-disciplinary telehealth service provider in Canada.  MyHealth will operate as a wholly-owned WELL subsidiary led by Suresh Madan, who will continue to serve as MyHealth’s CEO.

“We are delighted to be part of the entire WELL omni-channel patient services experience,” said Suresh Madan, President and CEO of MyHealth.  “Everything that WELL encompasses is aligned with our belief system, it’s a natural fit, and we feel we are positioned perfectly together for playing a leading role in advancing patient care in Canada.”

Transaction Details (all figures are in Canadian Dollars):

The Transaction was completed pursuant to a share purchase agreement dated June 4, 2021 (the “Agreement“).  The purchase price for the Transaction was $206M plus a future conditional earn-out of up to $60M .  Of such amount due on closing, $82M was paid in cash on the closing date.  An additional $94.3M was satisfied at a deemed price per share of $9.80, which was subject to an adjustment that was inversely proportional to the difference in the 5 day VWAP of WELL’s shares immediately prior to the closing date from the 5 day VWAP immediately prior to the signing of the Agreement (the “Adjustment“).  This Adjustment resulted WELL issuing 8,342.947 common shares on the closing date which are subject to certain volume based voluntary resale restrictions as provided in the Agreement.  The purchase price also consisted of the issuance of a convertible promissory note in the principal amount of $30M issued by WELL maturing in three $10M tranches on the third, sixth and ninth months following the closing date of the Transaction and repayable in cash, WELL common shares, or a combination of both at WELL’s discretion with a conversion price equal to the VWAP for the five days prior to the conversion date.  The earn-out is a four-year performance-based earn-out of up to $60M, payable in cash, WELL common shares or a combination of both at WELL’s discretion with shares issuable at the VWAP for the five days prior to the applicable payment date.  The performance-based earn-out is earnable based upon MyHealth maintaining and enhancing its profitability over the performance period.  If the earn-out is fully achieved, it will result in a purchase multiple that is materially lower than the purchase multiple at the time of closing.

The Transaction was financed in part by senior credit facilities for  an amount of up to $200M, with an initial committed amount of $140M and an accordion feature which enables MyHealth to borrow an additional $60M subject to satisfaction of usual and customary provisions.  The facilities are provided by a syndicate of banks led by the Royal Bank of Canada and inclusive of the Bank of Montreal, HSBC Bank Canada, The Toronto-Dominion Bank, ICICI Bank Canada and Laurentian Bank of Canada (collectively, the “Lenders“) and documented by way of a credit agreement dated July 15, 2021 (the “Credit Agreement“) between, among others, MyHealth, as borrower, Royal Bank of Canada, as administrative agent, and the Lenders.  The Credit Agreement matures on July 15, 2025 and interest on the facilities is accrued based on prime rate or CDOR for Canadian dollar loans and base rate or LIBOR for US dollar loans plus a margin calculated on the basis of the financial performance of MyHealth.  The security for the credit facilities is comprised entirely of the assets and share pledges of MyHealth and its subsidiaries.  The terms of the Credit Agreement are customary for a transaction of this nature.

Advisors and Counsel

Eight Capital acted as lead financial advisor to WELL, and Stifel GMP provided advisory services to WELL on the Transaction.

Clark Wilson LLP, Torys LLP, and Dentons LLP acted as legal counsel to WELL on the Transaction.  Blakes LLP acted as legal counsel on the credit facility financing.  Deloitte Corporate Finance Inc. acted as financial advisor and Gowling WLG (Canada) acted as legal counsel to MyHealth.

Footnotes:

  1. Earnings before interest, taxes, depreciation and amortization (“EBITDA“) and EBITDA margin (EBITDA divided by revenue) are each Non-GAAP measures. EBITDA and EBITDA margin should not be construed as alternatives to net income/loss determined in accordance with International Financial Reporting Standards (“IFRS“). EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. The Company believes that EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives. For EBITDA reconciliation to Net income, please refer to the Company’s most recent Management Discussion and Analysis on Sedar.com. EBITDA margin is EBITDA as a percentage of total revenue.
  2. MyHealth proforma revenues means the sum total of all MyHealth subsidiaries and acquisitions for the 12 month period ending Dec 2021.
  3. CAGR means compound annual growth rate and is a Non-GAAP measure. CAGR should not be construed as an alternative to net income/loss determined in accordance with IFRS. CAGR does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers.
spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.